121 results about "Tumor response" patented technology

Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy also described is a composition useful in the treatment of lymphoma.

The present invention provides identification of a thirty-five gene set that predicts the anticancer activity of inhibitors of the RAF/MEK/MAPK pathway, methods of qualifying cancer status in a subject, methods of identifying an anti-tumor response in a subject, methods of monitoring the efficacy of a therapeutic drug in a subject, and methods of identifying an agent useful in the treatment of a cancer based on expression of the thirty-five gene set.

A method for assessing a tumor's response to therapy, includes providing images of a first study of a patient and images of a second study of the patient, the second study occurring after the first study and after the patient undergoes therapy to treat a tumor, each study comprising first and second types of functional magnetic resonance (fMR) images, performing a first registration in which the images within each study are registered, performing a second registration in which reference images from both studies are co-registered, segmenting the tumor in an image of each of the second registered studies; and determining that first and second fMR measure differences exist between the segmented tumor's of the first and second studies, the first fMR measure difference being obtained from the first type of fMR images, the second fMR measure difference being obtained from the second type of fMR images.

Oligonucleotides bearing free, uncapped 5′ phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1β production. Bacterial RNA also induces type I IFN production. 5′ phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1β production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5′ triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1β production, in a target cell-specific manner.

The present invention provides a variant of an immunoglobulin variable domain including (A) at least one CDR region and (B) framework regions flanking the CDR region, wherein the variant also contains (a) a CDR region having added or substituted therein at least on binding sequence and (b) the flanking framework regions, wherein the binding sequence is heterelogous to the CDR and is an antigenic sequence from a MUC-1 binding sequence.

A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.

The present invention provides methods for enhancing the development of APC from precursor cells by administering a combination of GM-CSF and IL-4. The precursor cells include: cells contained in peripheral blood, CD14⁺ cells and precursors in bone marrow. Thus, administration of GM-CSF and IL-4 can be used as a form of cytokine immunotherapy. One embodiment of the present invention involves systemic administration of GM-CSF and IL-4. In this embodiment, APC are required to directly access tumor antigens as they exist in vivo within the patient. A further embodiment of the present invention involves co-administration of a tumor-associated or tumor-specific antigen, with GM-CSF and IL-4, to induce antigen-specific immunity mediated by APC. Yet another embodiment of the present invention describes systemic administration of GM-CSF and IL-4 to achieve reduced tumor burden.

The invention relates to a preparation method and application of an ultrasonic control type anti-tumor drug delivery system. The problems that existing tumor treatment drugs are low in drug loading capacity, are leaked when delivered, are low in tumor response sensitivity, slow in release and prone to causing drug resistance, and can not be controlled in vitro are solved effectively. The ultrasonic control type anti-tumor drug delivery system is established with hollow mesoporous titanium dioxide as the base body by being internally loaded with perfluorohexane and drug bleomycin, wrapped by an endogenous biological membrane-erythrocyte membrane and modified by tumor homing peptides; a nanoscale particle size distribution drug delivery system is prepared with hollow mesoporous titanium dioxide as the base body by being internally loaded with perfluorohexane and model drug bleomycin, wrapping surfaces of hollow mesoporous titanium dioxide by RBC, and being wrapped by an endogenous biological membrane-erythrocyte membrane; a tumor drug delivery system with a remote ultrasonic control function is established by modifying tumor homing peptide NGR tail ends with diacyl lipid.

Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

A computerized method for determining an objective tumor response to an anti-cancer therapy using one or more cross-sectional images can comprise receiving one or more cross-sectional images that comprise one or more cross-sectional slices of digital medical image data and identifying one or more target lesions within the one or more cross-sectional images. The method can also comprise analyzing at least one of the target lesions with an image-processing module configured to identify a total range of pixel intensities and restrict the total range of pixel intensities to a first restricted range that corresponds to pixel intensities representative of vascularized tumor. Further still, the method can comprise deriving a vascular tumor burden for the at least one of the one or more target lesions and determining the objective tumor response for the at least one of the one or more target lesions based on the vascular tumor burden.

The present disclosure describes gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

A method for isolating the bioactive component of the water-soluble extract of Uncaria tomentosa known as C-MED-100®, comprising (i) precipitating the spray drying carrier from C-MED-100®; (ii) using the resulting C-MED-100® to obtain a spotting mixture for thin layer chromatography (TLC); (iii) spotting the C-MED-100® spotting mixture on pre-run TLC plates and eluting the plates to obtain the fluorescing band with R_f=0.2-0.3; (iv) scraping off the R_f=0.2-0.3 band, eluting it in ammonia and freeze drying the eluted band to form a powder; and (v) extracting the powder with methanol to remove solubilized silica gel, concentrating the methanol solution and crystalizing the concentrated solution to obtain the bioactive component. The isolated bioactive component in vitro is a quinic acid analog, preferably quinic acid lactone. By contrast, the isolated bioactive component in vivo is quinic acid, whether as free acid or as a quinic acid salt, including quinic acid ammonium salt. A pharmaceutical composition comprising a pharmaceutically effective amount of the bioactive component and a nontoxic inert carrier or diluent. The bioactive component may be used to enhance immune competency, treat disorders associated with the immune system, inhibit the inflammatory response, treat disorders associated with the inflammatory response, enhance the anti-tumor response, and treat disorders associated with the response to tumor formation and growth, all in mammals.

The invention relates to ultra-wide band microwave imaging, ultra-wide band wireless detection, biomedical detection equipment and microwave detection, and in particular to a rapid imaging method for ultra-wide band microwave detection based on Hilbert-huang transformation. According to the method, biological information can be displayed simply, conveniently, rapidly and obviously. According to the technical scheme, the rapid imaging method includes the following steps that an antenna Ai is used for emitting ultra-wide band microwave signals, and other antennas are used for receiving reflecting signals from the inner portion of one breast so as to obtain signals containing tumor information and signals containing no tumor information; tumor response signals are obtained by subtracting the signals containing no tumor information from the signals containing the tumor information, Hilbert transform is conducted on all the obtained tumor response signals, the signals are constructed into analytical signals, and then the instantaneous amplitude of the signals is obtained; for a breast area, scanning is conducted on each point in an imaging area through a confocal imaging method, and the position and size information of a tumor is obtained clearly. The rapid imaging method is mainly used for designing and manufacturing medical apparatuses and instruments.

The invention relates to the field of immunology, endocrinology and oncology and, in particular, the generation of a combined immune response to determined growth factors and hormones. A synergic effect, outlined herein, between growth regulating factors (EGF, TGF and VEGF) and hormones involved in the sexual hormones release cascade or reproduction (GnRH, LH, FSH) stimulates the anti-tumor response which is expressed as a reduction in the tumor mass and an increase in the survival time.

Peptide motifs which define specificity of tumor-derived endothelial cells. These peptides possess a charge motif of positive-positive-hydrophobic which is important in determining the specificity of binding to tumor-derived endothelium. The specific molecular peptide motifs will facilitate diverse therapeutic and diagnostic applications including: anti-angiogenic therapies to be used in alone or in conjunction with standard therapies; imaging tools for both detection of very small metastasis that are undetectable by current techniques; for monitoring tumor response; for targeting and directing chemotherapy drugs to the tumor; for treatment of chronic inflammatory diseases such as rheumatoid arthritis and psoriasis, for treating some forms of blindness; as well as other diagnostic and therapeutic applications.